IMOSPHERE LTD

Their core work

Imosphere is a UK health data analytics company that builds collaborative software platforms for exploring population-level health data across national boundaries. Their core product is a pan-national analytics platform that allows health systems and researchers to query, compare, and draw insights from large population health datasets without centralising sensitive patient records. They progressed through the EU's SME Instrument pathway — from a Phase 1 feasibility study (iMoHEALTH) to a full Phase 2 development and market deployment grant (AtmoHealth) — demonstrating a validated and commercially investible product trajectory. Their work sits at the intersection of federated data access, population health intelligence, and cross-border health information systems.

What they specialise in

How they've shifted over time

Imosphere's H2020 participation follows a single, focused trajectory rather than a diversifying one: they identified a specific problem (fragmented population health data across nations) and methodically validated, then built, a platform to solve it. The 2014–2015 iMoHEALTH Phase 1 grant was a EUR 50,000 feasibility study, and the 2016–2018 AtmoHealth Phase 2 grant of EUR 1.26M was the full commercial development follow-through. There is no evidence of topic diversification — instead, this represents deepening commitment to a single product concept, which is either a sign of strong product-market focus or limited organisational breadth.

Imosphere was on a clear scale-up trajectory through 2018; whether they have continued to grow their platform commercially post-H2020 is unknown, but their EU track record shows a company capable of executing from concept to funded product launch.

How they like to work

Imosphere operated as the sole coordinator on both H2020 projects with no recorded consortium partners — a pattern consistent with the SME Instrument, which is specifically designed for single-company grants rather than multi-partner consortia. This means they have no documented experience managing large EU research consortia, but they have demonstrated self-sufficient project management and delivery under EU grant conditions. For future collaborations, they would likely fit best as a technology provider or specialist subcontractor rather than a consortium orchestrator.

Imosphere's H2020 participation shows no recorded consortium partners or cross-border collaborations within the grant data — both grants were single-beneficiary SME Instrument awards. Their network reach within the EU funding system is narrow, though their pan-national platform concept implies engagement with health data stakeholders across multiple countries at the product level.

What sets them apart

Imosphere occupies a specific niche: a small UK company that built a cross-border population health analytics platform and secured over EUR 1.3M in EU validation grants to prove it. Unlike academic health informatics groups, they operate as a commercial entity with a market-facing product and a demonstrated ability to pass the competitive SME Instrument evaluation twice. Post-Brexit, their UK base may limit eligibility for current Horizon Europe funding, but their platform and domain expertise remain relevant for European health data infrastructure projects and commercial partnerships.

Highlights from their portfolio

• AtmoHealth
  The largest grant Imosphere received (EUR 1,258,821 under SME Phase 2), representing a full platform development and commercialisation push — a significant vote of confidence from EU evaluators in both the technology and the business model.
• iMoHEALTH
  The Phase 1 feasibility study that unlocked the Phase 2 grant, demonstrating Imosphere's ability to structure and pitch a viable health analytics concept at EU level from an early stage.